Navigation Links
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
Date:6/5/2008

BURLINGTON, N.C. and ROCKVILLE, M.D., June 5 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), one of the world's leading clinical trials and genetic testing laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced an exclusive alliance to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta(TM) (iloperidone), a novel atypical antipsychotic drug candidate under FDA review for the treatment of schizophrenia. Financial terms of the agreement were not disclosed.

Vanda has identified a series of pharmacogenetic markers during its development of Fanapta(TM), and the company continues its pioneering work in this area. Under the terms of the collaboration, LabCorp will be Vanda's exclusive commercialization partner for tests for genetic markers of the Fanapta(TM) program.

"Working with innovative companies like Vanda to commercialize predictive medicine tests is a critical strategic focus for LabCorp," said Andrew J. Conrad, Ph.D., Chief Scientist and Global Head of Clinical Trials for LabCorp. "This collaboration is an example of our commitment to the advancement of personalized medicine and represents a successful translation of a research based assay into a valuable diagnostic test. This relationship i
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... -- Emerson Ecologics is excited to announce its first ... . The conference will provide integrative healthcare practitioners with ... fulfilling practice. Scheduled for November 13-15, ... the conference will be a one-of-a-kind, "get it done" ... and leave with an action plan in hand. Highlights ...
(Date:4/1/2015)...  VLP Therapeutics, LLC. ("VLP"), a Gaithersburg ... development of therapeutic and preventative vaccines and next generation ... technology, today announced that it has entered into a research ... Nagasaki University in Japan ... development of dengue vaccine candidates. "I ...
(Date:4/1/2015)... , Apr. 1, 2015 Goldman Small Cap ... small cap and microcap sectors, announced today that it ... (OTCQB – PMCB), a publicly traded clinical stage biotechnology ... and diabetes. To view the sponsored research article, along ... its entirety, please visit www.GoldmanResearch.com .  ...
(Date:4/1/2015)... -- EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, ... appointment of Frederick E. Munschauer to Vice ... capacity, he will lead the medical affairs activities for ... Rebif ® (interferon beta-1a) as well as the ... Munschauer joins EMD Serono from Biogen, bringing more than ...
Breaking Biology Technology:Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5
... April 3, 2008 Spherix,Incorporated (Nasdaq: SPEX ) ... December 31, 2007. The Company,s research and development costs,jumped ... with the launch of,the Company,s Phase 3 clinical trial ... April 2007. The trial is expected to last at ...
... Development, PLEASANTON, Calif., April 3, 2008 ... its new research facility,at the company,s global headquarters ... of consolidation of RMD,s West Coast,operations into one ... 500,employees, including 120 members of RMD,s research teams ...
... 3, 2008 Ratcliff, the,award-winning architecture, planning and ... 380,000-square-foot patient care tower,accompanied by a 767-stall parking ... Medical Center - Walnut Creek Campus. The Thomas ... recently broke ground will add,230 private and six ...
Cached Biology Technology:Spherix Reports 2007 Financial Results 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 3
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... to the puzzle of scaling how patterns stay in ... develops. In a new study appearing in Current Biology, Institute ... Danny Ben-Zvi of the Molecular Genetics Department have shown how ... the vein structure stays perfectly proportioned and their findings ...
... Male adult helminthomorph millipedes usually have one or ... into sexual appendages. These specialized gonopods are used as ... transfer sperm. New research published in BioMed Central,s open ... in detail at millipede development and the internal reorganization ...
... have published papers that associate chronic stress with chromosomal ... have discovered a mechanism that helps to explain the ... "We believe this paper is the first to propose ... stress, elevated adrenaline, could eventually cause DNA damage that ...
Cached Biology News:Scale models 2The secret life of millipedes 2At last, a reason why stress causes DNA damage 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: